**Education** 2000-2002 Postdoctoral Fellow, Department of Dermatology, MD Anderson Cancer Center, University of Texas, USA 1998-1999 Postdoctoral Fellow, Department of Dermatology, University Hospital Zurich, Switzerland 1990-1995 M.D., Dermatology and Venereology, Beijing Medical University (now Peking University Health Science Center) **Professional Experience** 2024- Vice President, Yan'an Branch of Peking University Third Hospital 2019- Deputy Director, National Clinical Research Center for Skin and Immune Diseases 2015-2018 Chair, Department of Dermatology and Venereology, Peking University Health Science Center 2012- Distinguished Professor and Doctoral/Postdoctoral Supervisor, Department of Dermatology, Peking University Third Hospital 2012-2022 Director, Department of Dermatology, Peking University Third Hospital 2003-2012 Instructor and Assistant Professor, Department of Dermatology, MD Anderson Cancer Center, University of Texas, USA 1995-1999 Attending Physician, Associate Chief Physician, and Deputy Director, Department of Dermatology, Peking University Third Hospital **Research Activities** **1. Representative Scientific Research Grants (PI)** 1) Beijing Municipal Natural Science Foundation General Project (2020) *Study on the Effect and Regulatory Mechanism of LncRNA-RN7SL1 on Proliferation of Cutaneous T-Cell Lymphoma Cells* 2) Key-Area Research and Development Program of Guangdong Province, Sub-project (2020) *Clinical Evaluation and Multi-omics Mechanism Exploration of Optimized Integrated Traditional Chinese and Western Medicine Regimens for Moderate-to-Severe Psoriasis with Blood Stasis Syndrome* 3) National Natural Science Foundation of China General Project (2019) *Study on the Effect and Regulatory Mechanism of LncRNA-HOTAIRM1 on Proliferation of Cutaneous T-Cell Lymphoma Cells* 4) Sub-project of the Key Laboratory of Dermatology, Ministry of Education (2018) *Pharmacogenomic Study of Cyclosporine in the Treatment of Erythrodermic Psoriasis* 5) Peking University "Double First-Class" Advantageous Discipline Construction Project (2017) *Dermatology and Venereology* 6) National Natural Science Foundation of China General Project (2014) *Resistance to Histone Deacetylase Inhibitors in Cutaneous T-Cell Lymphoma and Combination Therapy Strategies* 7) Beijing Municipal Science and Technology Commission, Capital Clinical Characteristic Application Research Special Fund (2013) *Establishment of a Skin Cancer Biobank and Early Screening and Warning System* 8) Peking University Third Hospital Talent Introduction Research Startup Fund (2012) *Establishment of the Cutaneous Oncology Center* 9) Ladies Leukemia League Research Grant, USA (2007) *Selective anti-tumor activity of HDAC inhibitors in cutaneous T-cell lymphoma: from bench to bedside & back* 10) Dermatology Foundation Research Grant, USA (2006) *Translational study of histone deacetylase inhibitor SAHA in CTCL* **2. Major Clinical Trial Research Projects (PI)** 1) Pfizer Pharmaceuticals Co., Ltd. (2019) *A Phase IIB/III, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of PF-06651600 in Adult and Adolescent Subjects with Alopecia Areata (AA) with ≥50% Scalp Hair Loss* 2) Reistone Biopharma Co., Ltd. (2019) *A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR0302 in Adult Patients with Moderate-to-Severe Atopic Dermatitis* 3) AbbVie Pharmaceutical Trading (Shanghai) Co., Ltd. (2019) *A Phase III, Randomized, Placebo-Controlled, Double-Blind Study Evaluating Upadacitinib in Adolescent and Adult Subjects with Moderate-to-Severe Atopic Dermatitis* 4) Sanofi (China) Investment Co., Ltd., Shanghai Branch (2019) *A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of DUPILUMAB in Adult Patients with Moderate-to-Severe Atopic Dermatitis in China* 5) Peking University Third Hospital & Tianjin Changhe Biotechnology Co., Ltd. (2018, filed with NHC) *Randomized, Positive-Controlled Trial Evaluating the Efficacy and Safety of Human Umbilical Cord Mesenchymal Stem Cell Injection for the Treatment of Patients with Moderate-to-Severe Plaque Psoriasis* 6) Lilly Suzhou Pharmaceutical Co., Ltd. (2018) *A Multicenter Study Evaluating the Efficacy and Safety of LY2439821 in Chinese Patients with Moderate-to-Severe Plaque Psoriasis, Including a Randomized, Double-Blind, Placebo-Controlled Induction Period and a Randomized Maintenance Period* 7) Novartis (China) Biomedical Research Co., Ltd. (2017) *A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study Evaluating the Efficacy and Safety of Xolair (Omalizumab) in Chinese Patients with Chronic Spontaneous Urticaria who Remain Symptomatic Despite Antihistamine Treatment* 8) LEO Pharma A/S, Denmark (2016) *A Large Study Evaluating the Long-Term Use of Xamiol Gel for the Treatment of Scalp Psoriasis in Chinese Adults* 9) Mundipharma (China) Pharmaceutical Co., Ltd. (2014) *A Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of 5% Lidocaine Patch (Transdermal Therapeutic System) versus Placebo Patch in Patients with Post-Herpetic Neuralgia (HZAP) Unresponsive to Placebo* 10) AstraZeneca (2013) *A Phase III, Multicenter, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of Ceftaroline Fosamil (600 mg every 8 hours) versus Vancomycin plus Aztreonam in Patients with Complicated Bacterial Skin and Skin Structure Infections and Evidence of Systemic Inflammatory Response or Underlying Comorbidities* **3. Representative SCI Publications (First/Corresponding Author)** 1) Wang YM, Li WW, Zhang Q, Gu XG, He XL, Men YH, Zhang CL. Targeting phosphorylation of p21-activated kinase 1 at Thr423 induces cell cycle arrest and apoptosis in cutaneous T-cell lymphoma cells. Acta Derm Venereol 99 (11): 1022-8, 2019. 2) Jiang WW, Wang YM, Wang XY, Zhang Q, Zhu SM, Zhang CL. Role and mechanism of matrine alone and combined with acitretin for HaCaT cells and psoriasis-like murine models. Chin Med J 132 (17): 2079-88, 2019. 3) Wang YM, Gu XG, Li WW, Zhang Q, Zhang CL. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21. J Dermatol Sci 90 (1): 60-7, 2018. 4) Zhang CL, Li BQ, Zhang X, Hazarika P, Aggarwal BB, Duvic M. Curcumin selectively induces apoptosis in cutaneous T-cell lymphoma cell lines and patients' PBMCs: potential role for STAT-3 and NF-kB signaling. J Invest Dermatol 130 (8): 2110-9, 2010. 5) Zhang CL, Li BQ, Gaikwad A, Haridas V, Xu ZX, Gutterman J, Duvic M. Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells. J Invest Dermatol 128 (11): 2728-35, 2008. 6) Zhang CL, Toulev A, Kamarashev J, Qin JZ, Dummer R, Döbbeling U. The consequences of p16 tumor suppressor gene inactivation in mycosis fungoides and Sézary syndrome and the role of the bmi-1 and ras oncogenes in disease progression. Hum Pathol 38 (7): 995-1002, 2007. 7) Zhang CL, Richon V, Ni X, Talpur R, Duvic M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 125 (5): 1045-52, 2005. 8) Zhang CL, Ni X, Konopleva M, Andreeff M, Duvic M. The novel synthetic oleanane triterpenoid CDDO induces apoptosis in mycosis fungoides/Sézary syndrome cells. J Invest Dermatol 123 (2): 380-7, 2004. 9) Zhang CL, Kamarashev J, Qin JZ, Dummer R, Burg G, Döbbeling U. Expression of apoptosis regulators in cutaneous T-cell lymphoma cells. J Pathol 200 (2): 249-54, 2003. 10) Zhang CL, Hazarika P, Ni X, Weidner DA, Duvic M. Induction of apoptosis by bexarotene in CTCL cells: relevance to mechanism of therapeutic action. Clin Cancer Res 8 (5): 1234-40, 2002. **Academic Appointments** 1. Committee Member, International Society for Cutaneous Lymphomas (